ISEE2008: Phase III clinical trial in patients with dry AMD 18/11/2020
تسجيل
DESCRIPTION
ISEE2008 (GATHER2): A multicentre, randomised, double-masked, simulation controlled phase III clinical trial to assess the safety and efficacy of the intravitreal administration of Zimura (C5 complement inhibitor) in patients with geographic atrophy secondary to dry age-related macular degeneration
INCLUSION CRITERIA
Patients older than 50 with non-foveal geographic atrophy secondary to dry age-related macular degeneration. They should not have received prior treatment or have exudative macular degeneration in the other eye. Vision should be between 20/25 and 20/320.
AIMS
The aims of this study are to assess the safety and efficacy of the intravitreal administration of Zimura in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD).
DURATION
The duration of the study is 2 years.
